273 related articles for article (PubMed ID: 33984593)
1. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.
Yang X; Feng Y; Liu Y; Ye X; Ji X; Sun L; Gao F; Zhang Q; Li Y; Zhu B; Wang X
Phytomedicine; 2021 Jul; 87():153575. PubMed ID: 33984593
[TBL] [Abstract][Full Text] [Related]
2. Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: a case-control trial.
Chen Z; Chen HY; Lang QB; Li B; Zhai XF; Guo YY; Yue XQ; Ling CQ
Chin J Integr Med; 2012 May; 18(5):339-44. PubMed ID: 22549390
[TBL] [Abstract][Full Text] [Related]
3. Effect of decoction of Fuzheng Jiedu Xiaoji formula plus chemoembolization on primary liver cancer in patients.
Tong WU; Zhiyun Y; Yuying Y; Yuyong J; Peipei M; Huimin L; Yehong T; Qiaoli Z
J Tradit Chin Med; 2022 Jun; 42(3):446-450. PubMed ID: 35610015
[TBL] [Abstract][Full Text] [Related]
4. Jiedu Recipe, a compound Chinese herbal medicine, inhibits cancer stemness in hepatocellular carcinoma via Wnt/β-catenin pathway under hypoxia.
Guo BJ; Ruan Y; Wang YJ; Xiao CL; Zhong ZP; Cheng BB; Du J; Li B; Gu W; Yin ZF
J Integr Med; 2023 Sep; 21(5):474-486. PubMed ID: 37453868
[TBL] [Abstract][Full Text] [Related]
5. In Silico and In Vitro Studies on the Mechanisms of Chinese Medicine Formula (Yiqi Jianpi Jiedu Formula) in the Treatment of Hepatocellular Carcinoma.
Wu Z; Kang J; Tan W; Wei C; He L; Jiang X; Peng L
Comput Math Methods Med; 2022; 2022():8669993. PubMed ID: 36345477
[TBL] [Abstract][Full Text] [Related]
6. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
7. Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV).
Zhu Z; Jia J; Lu R; Lu Y; Fu Z; Zhao L; Wang L; Jin M; Zhao L; Gao W; Yao Z
Int J Cancer; 2006 Mar; 118(6):1539-44. PubMed ID: 16184552
[TBL] [Abstract][Full Text] [Related]
8. Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway.
Huang Y; Liu C; Zeng WC; Xu GY; Wu JM; Li ZW; Huang XY; Lin RJ; Shi X
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840737
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
11. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J
Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856
[TBL] [Abstract][Full Text] [Related]
12. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma.
Huang H; Chen T; Zhou Y; Geng L; Shen T; Zhou L; Zheng S
Int J Med Sci; 2018; 15(14):1648-1657. PubMed ID: 30588188
[TBL] [Abstract][Full Text] [Related]
13. Diosgenin induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma cells.
Li Y; Wang X; Cheng S; Du J; Deng Z; Zhang Y; Liu Q; Gao J; Cheng B; Ling C
Oncol Rep; 2015 Feb; 33(2):693-8. PubMed ID: 25434486
[TBL] [Abstract][Full Text] [Related]
14. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
15. Fuzheng Xiaozheng prescription relieves rat hepatocellular carcinoma through improving anti-inflammation capacity and regulating lipid related metabolisms.
Li X; Yu H; Gong Y; Wu P; Feng Q; Liu C
J Ethnopharmacol; 2022 Feb; 284():114801. PubMed ID: 34748868
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
17. Investigating the molecular mechanism of Qizhu anticancer prescription in inhibiting hepatocellular carcinoma based on high-resolution mass spectrometry and network pharmacology.
Sun J; Ma M; Zhong X; Li J; Yi J; Zhang R; Liu X; Peng L; Sun X; Feng W; Hu R; Huang Q; Lv M; Fan K; Zhou X
J Ethnopharmacol; 2024 Jun; 328():117985. PubMed ID: 38417600
[TBL] [Abstract][Full Text] [Related]
18. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
